Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

Schizophrenia Research

Volumn 118, Issue 1-3, 2010, Pages 183-188

  Jager M ^a,b   Riedel, M ^a   Obermeier, M ^a   Schennach Wolff, R ^a   Seemuller F ^a   Messer, T ^c   Laux, G ^d   Pfeiffer, H ^e   Naber, D ^f   Schmidt, L G ^g   Gaebel, W ^h   Klosterkotter J ⁱ   Heuser, I ^j   Kuhn K U ^k   Lemke, M R ^l   Ruther E ^m   Klingberg, S ⁿ   Gastpar, M ^o   Bottlender, R ^a   Moller H J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c District Hospital Augsburg   (Germany)

^d Inn Salzach Hospital   (Germany)

^e KLINIKUM MÜNCHEN OST   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY OF BONN   (Germany)

^l Department of Psychiatry   (Germany)

^m UNIVERSITY OF GÖTTINGEN   (Germany)

ⁿ UNIVERSITY OF TÜBINGEN   (Germany)

^o UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

Remission; Response; Schizophrenia; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; FAMILY THERAPY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOEDUCATION; REMISSION; SCHIZOPHRENIA; SOCIAL ADAPTATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 77951975806     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.002     Document Type: Article

References (29)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action. A hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1234.
2. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington DC. 4th Edition (DSM-IV).
3. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
4. Beitinger R., Lin J., Kissling W., Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1643-1651.
5. Cesková E., Prikryl R., Kaspárek T., Ondrusová M. Psychopathology and treatment responsiveness of patients with first episode schizophrenia. Neurpsychiatr. Dis. Treat. 2005, 1:179-185.
6. Emsley R., Rabinowitz J., Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 2006, 163:743-745.
7. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World. J. Bio.l Psychiatry 2005, 6:132-191. WFSBP Task Force on Treatment Guidelines for Schizophrenia.
8. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) Clinical Version 1997, American Psychiatric Association, Washington DC.
9. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
10. Heerdink E.R., Stolker J.J., Meijer W.E., Hugenholtz G.W., Egberts A.C. Need for medicine-based evidence in pharmacotherapy. Br. J. Psychiatry 2004, 184:452.
11. Helldin L., Kane J.M., Karilampi U., Norlander T., Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr. Res. 2007, 93:160-168.
12. Jäger M., Riedel M., Messer T., Laux G., Pfeiffer H., Naber D., Gaebel W., Huff W., Schmidt L.G., Heuser I., Buchkremer G., Kühn K.U., Lemke M.R., Rüther E., Gastpar M., Bottlender R., Strauß A., Möller H.J. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257:47-53.
13. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., Jones B. Evidence of onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 2005, 162:939-946.
14. Kay S.R. Positive and negative syndromes in schizophrenia: assessment and research 1991, Clinical and experimental psychiatry monography No. 5 Brunner/Mazel, New York.
15. Lasser R.A., Bossie C.A., Gharabawi G.M., Kane J.M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 2005, 77:215-227.
16. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested confirmed and extended. Biol. Psychiatry 2005, 57:1543-1549.
17. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining "response" in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32:1903-1910.
18. Li M., Fletcher P.J., Kapur S. Time course of the antipsychotic effect and the underlying behavioural mechanisms. Neuropsychopharmacology 2007, 32:263-272.
19. Möller H.J. Do effectiveness ("real world") studies on antipsychotics tell us the real truth?. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258:257-270.
20. Obermeier M., Mayr A., Schennach-Wolff R., Seemüller F., Möller H.J., Riedel M. Should the PANSS be rescaled?. Schizophr. Bull 2009, 10.1093/schbul/sbp124.
21. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2008, R Development Core Team, http://www.R-project.org.
22. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
23. Tollefson D.G., Birkett M.A., Kiesler G.M., Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 2001, 49:52-63. Lilly Resistant Schizophrenia Study Group.
24. Van Os J., Drukker M., á Campo J., Meijer J., Bak M., Delespaul P. Validation of remission criteria for schizophrenia. Am. J. Psychiatry 2006, 163:2000-2002.
25. Weinmann S., Hoerger S., Erath M., Kilian R., Gaebel W., Becker T. Implementation of a schizophrenia practice guideline. Clinical results. J. Clin. Psychiatry 2008, 69:1299-1306.
26. Wittchen H.U., Wunderlich U., Gruschwitz S., Zaudig M. Strukturiertes klinisches Interview für DSM-IV (SKID) 1997, Hogrefe, Göttingen.
27. Wölwer W., Buchkremer G., Häfner H., Klosterkötter J., Maier W., Möller H.J., Gaebel W. German research network on schizophrenia. Bridging the gap between research and care. Eur. Arch. Clin. Neurosci. 2003, 253:321-329.
28. Wunderink L., Nienhuis F.J., Sytema S., Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr. Bull. 2007, 33:792-796.
29. Zimmermann J., Wolter A., Hannöver W., Krischke N. Frequency of remission in schizophrenia patients at one year follow-up. Psychiatr. Prax. 2009, 36:182-188.